Study wrapper · #1154
Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
Editor's note
A network meta-analysis of nine placebo-controlled trials that puts high-dose oral semaglutide at or near the top of the oral GLP-1 field for weight reduction in adults without diabetes. The caveat is structural: rankings rest on indirect comparisons across trials of different lengths and populations, and certainty is graded low to moderate. Still, this is a useful consolidation of where the oral options stand as the pill race with small-molecule agents heats up.
Plain-language abstract
This analysis pooled nine randomized trials (about 5,800 adults with overweight or obesity but no diabetes) testing oral GLP-1 pills against placebo. High-dose oral semaglutide cut body weight by about 11.6% versus placebo — essentially tied with the non-peptide pill orforglipron — and produced the largest reductions in BMI and waist circumference. The comparisons are indirect, though, since the drugs were never tested head to head, and the authors rate the certainty as low to moderate.